Centocor Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Philadelphia PA United States (1979)
Status: Acquired by Johnson and Johnson (1999)

Organization Overview

First Clinical Trial
1991
NCT00269893
First Marketed Drug
1992
muromonab cd3 (Orthoclone OKT3)
First NDA Approval
1992
muromonab cd3 (Orthoclone OKT3)
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Centocor BV | Centocor, Inc. | CENTOCOR INC | Centocor Ortho Biotech, Inc. | Centocor Ortho Biotech Products, L.P. | Centocor Ortho Biotech Services, L.L.C. | Centocor Research & Development, Inc.

Active Ingredients

Marketed Drugs (4)

abciximab (Reopro) (1994)

imciromab pentetate (myoscint) (1996 NDA)

infliximab (remicade) (1998)

muromonab cd3 (Orthoclone OKT3) (1992 NDA)

Drugs in Phase 4 Trials (7)

Key: Centocor (4) Acquired (3)

azathioprine (imuran) (2 trials)

budesonide (rhinocort) (1 trial)

epoetin (Epogen) (60 trials)

infliximab (remicade) (46 trials)

iron (1 trial)

methylprednisolone (medrol) (3 trials)

sodium chloride (1 trial)

Drugs in Phase 3 Trials (14)

Key: Centocor (9) Acquired (5)

abciximab (Reopro) (6 trials)

alteplase (Activase) (1 trial)

bortezomib (velcade) (8 trials)

etanercept (enbrel) (2 trials)

golimumab (simponi) (16 trials)

heparin (liquaemin) (1 trial)

interferon alpha-2b (Intron-A) (4 trials)

naltrexone (revia) (9 trials)

reteplase (Retavase) (1 trial)

ribavirin (virazole) (4 trials)

siltuximab (sylvant) (8 trials)

streptokinase (streptase) (1 trial)

urea (6 trials)

ustekinumab (stelara) (13 trials)

Drugs in Phase 2 Trials (27)

Key: Centocor (5) Acquired (22)

azacitidine (vidaza) (1 trial)

bevacizumab (avastin) (3 trials)

carboplatin (paraplatin) (3 trials)

carlumab (4 trials)

cyclophosphamide (cytoxan) (6 trials)

cytarabine (cytosar-u) (1 trial)

dacarbazine (dtic-dome) (1 trial)

darbepoetin alfa (aranesp) (1 trial)

docetaxel (taxotere) (4 trials)

doxorubicin (Doxil) (25 trials)

estramustine (emcyt) (1 trial)

Filgrastim (neupogen) (2 trials)

gemcitabine (gemzar) (3 trials)

intetumumab (3 trials)

lenalidomide (revlimid) (1 trial)

mesna (mesnex) (1 trial)

mitoxantrone (novantrone) (1 trial)

paclitaxel (taxol) (3 trials)

prednisone (meticorten) (7 trials)

rituximab (rituxan) (5 trials)

rv568 (4 trials)

sargramostim (leukine) (2 trials)

sirukumab (3 trials)

thalidomide (Thalomid) (3 trials)

trastuzumab (herceptin) (1 trial)

vincristine (oncovin) (4 trials)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (12)

Key: Centocor (6) Acquired (6)

cnto 2476 (1 trial)

cnto 3157 (1 trial)

cnto 3649 (1 trial)

cnto-5825 (1 trial)

guselkumab (tremfya) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

jnj-38877605 (1 trial)

rv1162 (1 trial)

rv1729 (3 trials)

rv6153 (1 trial)

vorinostat (zolinza) (1 trial)

zarnestra (1 trial)

Drugs in Other Trials (6)

Key: Centocor (0) Acquired (6)

asparaginase (elspar) (1 trial)

autologous mononuclear stem cell (1 trial)

enoxaparin (lovenox) (1 trial)

melphalan (alkeran) (2 trials)

platelets (1 trial)

red blood cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 3)

Anemia (Phase 2)

Angina Pectoris (Phase 3)

Angina, Unstable (Phase 3)

Arteritis (Phase 2)

Arthritis (Phase 4)

Arthritis, Juvenile (Phase 3)

Arthritis, Psoriatic (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Asthma (Phase 2)

Berylliosis (Phase 2)

Brain Ischemia (Phase 3)

Cachexia (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Castleman Disease (Phase 1)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Colorectal Neoplasms (Phase 2)

Crohn Disease (Phase 4)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Fallopian Tube Neoplasms (Phase 2)

Fibrosis (Phase 2)

Giant Cell Arteritis (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hyperplasia (Phase 1)

Idiopathic Pulmonary Fibrosis (Phase 2)

Infarction (Phase 3)

Ischemia (Phase 3)

Kidney Diseases (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Lung Neoplasms (Phase 2)

Lupus Erythematosus, Cutaneous (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 2)

Mucocutaneous Lymph Node Syndrome (Phase 1)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myocardial Infarction (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Osteoarthritis (Phase 4)

Osteoarthritis, Knee (Phase 4)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Parapsoriasis (Phase 3)

Peritoneal Neoplasms (Phase 2)

Polymyalgia Rheumatica (Phase 2)

Preleukemia (Phase 3)

Prostatic Neoplasms (Phase 2)

Psoriasis (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Pulmonary Fibrosis (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Retinitis (Phase 1)

Retinitis Pigmentosa (Phase 1)

Sarcoidosis (Phase 3)

Sclerosis (Phase 2)

Spondylarthritis (Phase 4)

Spondylarthropathies (Phase 4)

Spondylitis (Phase 4)

Spondylitis, Ankylosing (Phase 4)

Stroke (Phase 3)

Syndrome (Phase 3)

Ulcer (Phase 3)

Wasting Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 203
  • # of Trial APIs: 66